Dr. Reddy’s Laboratories has launched an over-the-counter (OTC) eye drop solution, Olopatadine Hydrochloride Ophthalmic Solution, in the US market. The solution is a generic equivalent of Extra Strength Pataday Once-Daily Relief, which is used to provide temporary relief from itchy eyes caused by pollen, ragweed, grass, animal hair, and dander. The launch was approved by the US Food and Drug Administration (USFDA).
According to Milan Kalawadia, CEO of North America Generics at Dr. Reddy’s Laboratories, the launch is a significant addition to the company’s existing portfolio in the OTC eye-care space. The company already offers Olopatadine Hydrochloride Ophthalmic Solution, and this new launch further expands its presence in the market. Kalawadia also highlighted the company’s capabilities in bringing store-brand equivalents of OTC brands to the US market, citing the first-to-market launch as a testament to these capabilities.
The Pataday brand, which Dr. Reddy’s solution is equivalent to, had significant sales in the US market, with approximately $69.9 million in sales over the 52-week period ending December 27, 2025. This indicates a substantial market demand for the product, and Dr. Reddy’s launch is likely to capitalize on this demand.
The launch of Olopatadine Hydrochloride Ophthalmic Solution is a strategic move by Dr. Reddy’s to expand its presence in the US OTC market. The company’s ability to bring generic equivalents of popular brands to the market can help increase accessibility and affordability of these products for consumers. With its strong portfolio in the OTC eye-care space, Dr. Reddy’s is well-positioned to compete in the market and provide consumers with high-quality, affordable options for their eye care needs.
Overall, the launch of Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution is a significant development in the US OTC market, and the company’s capabilities in bringing generic equivalents to the market are likely to have a positive impact on consumers and the industry as a whole.